Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oragenics Inc
OGEN
Healthcare
Biotechnology
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for...
treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSEAM:OGEN)
New Post
View:
Posts & Comments
Threaded Posts
(170)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 04, 2024 5:17pm
BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Ente
Breaking News: $OGEN BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M2024-09-04 14:21:26 ET Oragenics (NYSE American: OGEN) , a
...more
(170)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 19, 2024 7:00pm
BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Repo
Breaking News: $OGEN BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion2024-08-19 10:44:57 ET Oragenics (NYSE American: OGEN)
...more
(9)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 03, 2024 3:09pm
Oragenics, Inc. (OGEN): Intranasal Drug Delivery Platform Of
https://beyondspx.com/2024/08/03/oragenics-inc-ogen-intranasal-drug-delivery-platform-offers-promising-concussion-treatment/
(170)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 10, 2024 10:47am
Oragenics Improves Intranasal Drug Formulation for Treating
JUST IN: $OGEN Oragenics Improves Intranasal Drug Formulation for Treating Concussed PatientsSARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused
...more
(170)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 25, 2024 5:15pm
Oragenics, Inc. Announces Pricing of Public Offering
JUST IN: $OGEN Oragenics, Inc. Announces Pricing of Public OfferingSARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique
...more
(170)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 07, 2024 11:45am
Oragenics, Inc. Announces Expiration of Its Investment Banki
JUST IN: $OGEN Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement AgreementOragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle
...more
(170)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 05, 2024 6:00pm
Oragenics, Inc. Preparing for Phase II Clinical Trials to Tr
BREAKING NEWS: $OGEN Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat ConcussionOragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle
...more
(170)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 23, 2024 9:45pm
Oragenics Announces Termination of At-The-Market Offering Pr
NEWS: $OGEN Oragenics Announces Termination of At-The-Market Offering ProgramOragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today
...more
(0)
•••
Peng26
X
View Profile
View Bullboard History
Post by
Peng26
on Apr 13, 2023 5:36am
FSD Pharma Inc is about to launch this breakthrough product
Kevin Harrington Speaks about FSD Pharma
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >